Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis

Published:2013-08-20 Issue:3 Volume:76 Page:348-357
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Qi Wei-Xiang¹,He Ai-Na¹,Shen Zan¹,Yao Yang¹

Affiliation:

1. Department of Oncology, The Sixth People's Hospital; Shanghai Jiao Tong University; Shanghai; 200233; China

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.12149/fullpdf

Reference39 articles.

1. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer;Ferrara;Nat Rev Drug Discov,2004

2. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3;Hu-Lowe;Clin Cancer Res,2008

3. U.S. Food and Drug Administration FDA Briefing Document, Oncologic Drugs Advisory Committee Meeting, NDA 20324 Axitinib (Inlyta) 2011 http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM282290.pdf

4. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study;Kindler;Lancet Oncol,2011

5. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study;Spano;Lancet,2008

Cited by 102 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemic hypertension with VEGFR inhibitor (axitinib) therapy in cancer patients: A meta-analysis and systematic review of randomized controlled trials;IJC Heart & Vasculature;2024-06

2. Theoretical investigation of fullerene (C60) as nano carrier for anti-cancer drug Axitinib;Carbon Trends;2024-03

3. Evaluation of Apatinib-Related Hypertension and Identification of Clinical Risk Factors;Journal of Clinical Pharmacy and Therapeutics;2024-01-25

4. Aneurysm and Artery Dissection After Oral VEGFR-TKI Use in Adults With Cancer;JAMA Network Open;2023-11-29

5. AXITINIB-ASSOCIATED HYPERTENSIVE EMERGENCY PRESENTING AS FLASH PULMONARY EDEMA;CHEST;2023-10